Vendor Intelligence Report: Rayshine Peptide Biochemicals

Executive summary

Rayshine is not a broad-catalog green light; it is a narrow Retatrutide case with serious documentation risk around the edges. Across 7 Finnrick lab tests, the overall pass rate is 71% (5 pass / 2 fail). Every Finnrick-covered sample in the supplied rollup is Retatrutide, so that product has some independent signal, but the spread is uneven enough that stricter buyers will read the methodology-divergence chart more cautiously.

The strongest buyer-useful takeaway is product separation. Retatrutide is the only Rayshine item with repeated Finnrick coverage and is therefore the only place where a data-backed vendor-specific argument can be made. HGH 191AA sits in a very different risk bucket: the report reconstructs a buyer-submitted fake-product incident and a later COA trail that moves the problem from bad sample to document-trust failure. Semaglutide, Tirzepatide, BPC-157, TB-500, GHK-Cu, and the rest of the catalog do not get the benefit of the Retatrutide data.

The corporate and operating record is also thin. Rayshine presents as a 2019 Xi’an peptide manufacturer, but independent web, certificate, registry, and marketplace artifacts point to a much younger public footprint, a template-built export site, inconsistent B2B location data, and placeholder brand controls. The report also separates genuine vendor-submitted Janoshik launch COAs from documents and shipment descriptions that create materially different buyer risk.

Fulfillment reports are not ignored: buyers describe FedEx deliveries and workable communication. But delivery reliability does not solve authenticity, customs, or payment-recourse exposure, especially where one reported shipment description masked peptides as a cosmetic item and the vendor accepts irreversible rails.

Inside the full report:

• Appendix A Finnrick laboratory data with Retatrutide test history and methodology-divergence charts
• Janoshik report verification analysis for the vendor-submitted GLP-1 launch COAs
• HGH 191AA fake-product and forged-COA incident reconstruction
• Corporate traceability review covering registry searches, claimed Xi’an address, and TradeWheel discrepancies
• Website-infrastructure assessment of the 400301 / diymysite template ecosystem and related-name domains
• Shipping, customs-label, payment-recourse, and buyer-community evidence matrix

Risk assessment

• HGH 191AA fake-product risk — high: Buyer-submitted Janoshik testing in the community record reported Rayshine HGH 191AA as 100% fake.
• Forged-COA and document-reliability risk — high: Rayshine reportedly supplied MZ BioLabs COAs that MZ BioLabs confirmed to a buyer were forged; all vendor PDFs require direct lab verification.
• Customs mislabeling and seizure risk — high: At least one shipment was reportedly declared as “freeze dried facial masks” rather than peptides, creating false-declaration and seizure exposure.
• Corporate traceability risk — high: The claimed 2019 Ruixing entity and Xi’an factory address were not corroborated in public registry searches; TradeWheel lists inconsistent location data and a reused-looking kk-import-export slug.
• Retatrutide batch-variability risk — medium: Retatrutide is Rayshine’s only Finnrick-covered product in the supplied rollup, with 7 tests, 5 pass, 2 fail, and a 76.97% current rating.
• Catalog verification gap — medium: Finnrick’s supplied independent rollup covers Retatrutide only; products such as Semaglutide, Tirzepatide, BPC-157, TB-500, GHK-Cu, and HGH 191AA lack comparable Finnrick coverage here.
• Irreversible-payment recourse risk — medium: Rayshine accepts BTC, USDT, and bank transfer / TT, which provide little recourse if a product is fake, seized, or not delivered.